Acceptability of aspirin for cancer preventive therapy: a survey and qualitative study exploring the views of the UK general population.
Kelly E LloydLouise H HallLucy ZieglerRobbie FoySophie M C GreenMairead MacKenzieDavid G TaylorSamuel George Smithnull nullPublished in: BMJ open (2023)
Among the general population, those with a personal or family history of cancer may be more receptive towards taking aspirin for preventive therapy. Future policies and campaigns recommending aspirin may be of particular interest to these groups. Multiple considerations about the benefits and risks of aspirin highlight the need to support informed decisions on the medication.
Keyphrases
- low dose
- cardiovascular events
- antiplatelet therapy
- papillary thyroid
- squamous cell
- public health
- anti inflammatory drugs
- acute coronary syndrome
- lymph node metastasis
- percutaneous coronary intervention
- stem cells
- emergency department
- coronary artery disease
- squamous cell carcinoma
- mesenchymal stem cells
- cardiovascular disease
- cross sectional
- bone marrow
- smoking cessation
- adverse drug
- atrial fibrillation